1. Feasibility of proton pencil beam scanning treatment of free-breathing lung cancer patients
- Author
-
Christian Richter, Antje Knopf, Rosalind Perrin, and Annika Jakobi
- Subjects
Lung Neoplasms ,INTERPLAY ,Proton ,medicine.medical_treatment ,interplay ,MITIGATION ,Radiation Dosage ,Radiosurgery ,030218 nuclear medicine & medical imaging ,Motion ,03 medical and health sciences ,0302 clinical medicine ,Interplay effect ,TARGETS ,motion ,PARTICLE THERAPY ,Proton Therapy ,medicine ,proton therapy ,Journal Article ,Humans ,Radiology, Nuclear Medicine and imaging ,Four-Dimensional Computed Tomography ,Radiometry ,Lung cancer ,Pencil-beam scanning ,Proton therapy ,Retrospective Studies ,Particle therapy ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Respiration ,Respiratory motion ,pencil beam scanning ,Hematology ,General Medicine ,QUANTIFICATION ,medicine.disease ,lung cancer ,Oncology ,RESPIRATORY MOTION ,030220 oncology & carcinogenesis ,SIMULATION ,Feasibility Studies ,Artifacts ,Nuclear medicine ,business ,Free breathing ,TUMOR MOTION - Abstract
BACKGROUND: The interplay effect might degrade the dose of pencil beam scanning proton therapy to a degree that free-breathing treatment might be impossible without further motion mitigation techniques, which complicate and prolong the treatment. We assessed whether treatment of free-breathing patients without motion mitigation is feasible.MATERIAL AND METHODS: For 40 lung cancer patients, 4DCT datasets and individual breathing patterns were used to simulate 4D dynamic dose distributions of 3D treatment plans over 33 fractions delivered with an IBA universal nozzle. Evaluation was done by assessing under- and overdosage in the target structure using the parameters V90, V95, V98, D98, D2, V107 and V110. The impact of using beam-specific target volumes and the impact of changes in motion and patient anatomy in control 4DCTs were assessed.RESULTS: Almost half of the patients had tumour motion amplitudes of less than 5 mm. Under- and overdosage was significantly smaller for patients with tumour motion below 5 mm compared to patients with larger motion (2% vs. 13% average absolute reduction of V95, 2% vs. 8% average increase in V107, p CONCLUSION: Tumour motion amplitude is an indicator of dose degradation caused by the interplay effect. Fractionation reduces the dose degradation allowing the unmitigated treatment of patients with small tumour motions of less than 5 mm. The beam-specific target approach improves the dose coverage. The tumour motion and position needs to be assessed during treatment for all patients, to quickly react to possible changes, which might require treatment adaptation.
- Published
- 2018